美股市場個股詳情

CAPR Capricor Therapeutics

添加自選

5.455
+0.045+0.83%

交易中 04/29 09:40 (美東)

1.72億總市值-6572市盈率TTM

Capricor Therapeutics股票討論區

登錄發表評論

Trytosaveabit

04/24 21:01

Update

$Capricor Therapeutics(CAPR.US)$ Capricor Therapeutics Announces Positive Type-B Meeting With FDA for Cap-1002 Program for Duchenne Muscular Dystrophy

Trytosaveabit

02/27 21:34

$Capricor Therapeutics(CAPR.US)$ Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
4 MINUTES AGO, 8:30 AM EST
VIA GLOBENEWSWIRE

GainorsOnHammers

02/24 01:30

$Capricor Therapeutics(CAPR.US)$ we'll. see $5.34 soon.

Moomoo AI

02/03 20:28

Investors' expectations of limited future growth may be causing the low P/S ratio. These conditions form a barrier for the share price unless improved. Consider other vital risk factors before investing in Capricor Therapeutics.

Revenues Working Against Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Share Price Following 25% Dive

Trytosaveabit

01/11 22:08

Update

$Capricor Therapeutics(CAPR.US)$Moomoo 24/7· just. Capricor Therapeutics Receives First Milestone Payment Of $10M From Nippon Shinyaku, Co. Under Exclusive Commercialization And Distribution Agreement

Moomoo AI

2023/12/13 03:10

Capricor Therapeutics is anticipated to see limited growth in the future, keeping its P/S ratio low. Despite recent growth, its muted future outlook compared to the overall industry could remain a barrier for its share price.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Surges 29% Yet Its Low P/S Is No Reason For Excitement

Trytosaveabit

2023/11/15 05:11

Watching closely!

$Capricor Therapeutics(CAPR.US)$ Looking for lots of updates/PR on a couple of their drug trials before EOY

Trytosaveabit

2023/09/29 20:01

UPDATE!

$Capricor Therapeutics(CAPR.US)$ Item 7.01
Regulation FD Disclosure.
On September 29, 2023, the Company announced a positive outcome from a Type-B clinical meeting with the U.S. Food and Drug Administration (the “FDA”) on the design and execution of HOPE-3, the Phase 3 pivotal trial of CAP-1002 in Duchenne Muscular Dystrophy (“DMD”). Feedback from the FDA on the proposed key clinical and regulatory requirements confirms CAP-1002’s path towards Biologics License Application (“BLA”) submiss...